Logo Prima Biomed

Welcome to the Newsroom

29 June 2015

A Message from the Chairman


Dear Fellow Shareholders of Prima BioMed,

It is with great pleasure that we invite you to attend an Extraordinary General Meeting of shareholders of our company, to be held in Sydney on 31 July 2015.

This meeting will be one of the more important to be held in Prima’s 14 years as a listed biotech company. If the resolutions being put before our shareholders are passed, they will enable significant funding for the exciting immunooncology programs added to our portfolio through the acquisition of Immutep SA late last year. The resolutions will also enable a significant investment in Prima from the US-based Ridgeback Capital Investments, whose  willingness to back Prima, we believe, constitutes a significant step forward for our company in terms of its credibility with key opinion leaders in Life Sciences investments.

We will now set out a brief explanation and context for each of the proposed resolutions in the Notice of Meeting.